Clinical Trials Directory

Trials / Completed

CompletedNCT01291836

Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study

Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)

Status
Completed
Phase
Study type
Observational
Enrollment
930 (actual)
Sponsor
Alere San Diego · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidney injury. It is also believed that patients who are admitted to the hospital with high NGAL levels in the blood/urine will have poorer outcomes.

Conditions

Timeline

Start date
2010-12-01
Primary completion
2013-10-01
Completion
2015-06-01
First posted
2011-02-09
Last updated
2024-01-03
Results posted
2018-02-19

Locations

13 sites across 7 countries: United States, Greece, Ireland, Italy, Netherlands, Spain, Switzerland

Source: ClinicalTrials.gov record NCT01291836. Inclusion in this directory is not an endorsement.

Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study (NCT01291836) · Clinical Trials Directory